Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
Date:2/5/2009

ATLANTA, Feb. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that 2008 fourth quarter and year end financial results will be released on Thursday, February 19, 2009. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 19, 2009, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available February 19 through February 26 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 312509.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

http://www.cryolife.com.

    D. Ashley Lee                                   Katie Brazel
    Executive Vice President,                       Fleishman Hillard
    Chief Financial Officer and                     Phone: 404-739-0150
    Chief Operating Officer
    Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
2. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
3. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
4. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
5. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
6. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
7. CryoLife to Present at UBS Global Life Sciences Conference
8. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
9. CryoLife Announces Management Promotions
10. CryoLifes Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
11. CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 23, 2017 , ... The Academy of Model Aeronautics (AMA), ... Association (UAA), the unifying voice for collegiate aviation education, are launching a joint ... and success through a STEM-based education platform. , Much like the program currently ...
(Date:6/22/2017)... , ... June 21, 2017 , ... ... office in North Carolina, and engages Timothy Reinhardt to manage the new site. ... leadership at Pfizer Inc, with his most recent role as the Director of ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to ... from hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are ...
(Date:6/22/2017)... ... June 22, 2017 , ... For the months ... produced a Spotlight series on “Cell Therapy Regulation” for its regenerative ... experts on the unique regulatory challenges of stem cell medical research. , Stem ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):